LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 55

Search options

  1. Article ; Online: Allergologische Diagnostik 2021.

    Zieglmayer, Petra

    Laryngo- rhino- otologie

    2022  Volume 101, Issue 8, Page(s) 673–686

    Abstract: Allergic diseases are among the most common diseases worldwide. For appropriate management knowledge of the allergy trigger is crucial. The clinical picture of allergic diseases is diverse and correct diagnosis is often a challenge. The allergist needs ... ...

    Title translation Allergy Diagnostics 2021.
    Abstract Allergic diseases are among the most common diseases worldwide. For appropriate management knowledge of the allergy trigger is crucial. The clinical picture of allergic diseases is diverse and correct diagnosis is often a challenge. The allergist needs to distinguish intolerances from allergies and infectious diseases from non-infectious triggers. Test results have to be interpreted accordingly to differentiate sensitizations from allergies. In this review current state of the art diagnostic measures to diagnose type I and type IV allergies are described and discussed.Immediate type allergies such as allergic rhinoconjunctivitis, asthma and anaphylaxis are mediated by allergen-specific IgE antibodies detectable both in serum and tissue. Typical triggers are pollen, mites, animal epithelia, food, insect toxins and pharmaceuticals. In everyday practice, diagnostics are based on three complementary pillars: the allergy-specific anamnesis as a prerequisite of correct interpretation of subsequent diagnostic tests like skin testing and serological immunoglobulin detection. These can be supplemented as required and available by provocation tests to prove clinical reactivity and cellular assays to demonstrate the cellular immune response.Type IV allergic reactions are mediated by T cells causing contact allergy with a local eczematous reaction with a latency of several hours to days. Some 3,500 triggers, often from occupational environment, are known; e. g., nickel, chromium, cobalt, fragrances, rubber, plastics, preservatives, dyes, neomycin, benzocaine, sulfonamides, quinidine, wool wax, perubalsam, eye therapeutics, light filter substances, disinfectants, pesticides, technical oils or plants. Diagnosis of contact allergy combines the history of cutaneous exposure with associated symptoms and patch testing, with detection of a late phase clinical reaction after 6 to 48, up to a maximum of 96 hours after antigen contact.
    MeSH term(s) Allergens ; Anaphylaxis ; Dermatitis, Allergic Contact/diagnosis ; Dermatitis, Allergic Contact/etiology ; Food ; Humans ; Skin Tests/adverse effects
    Chemical Substances Allergens
    Language German
    Publishing date 2022-08-01
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 96005-6
    ISSN 1438-8685 ; 0340-1588 ; 0935-8943
    ISSN (online) 1438-8685
    ISSN 0340-1588 ; 0935-8943
    DOI 10.1055/a-1856-2765
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Allergologische Diagnostik 2021

    Zieglmayer, Petra

    Laryngo-Rhino-Otologie

    2022  Volume 101, Issue 08, Page(s) 673–686

    Keywords Typ I-Allergie ; Typ IV-Allergie ; Hauttest ; Komponentendiagnostik ; type I allergy ; type IV allergy ; skin test ; component resolved diagnostics
    Language German
    Publishing date 2022-08-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 96005-6
    ISSN 1438-8685 ; 0935-8943 ; 0340-1588
    ISSN (online) 1438-8685
    ISSN 0935-8943 ; 0340-1588
    DOI 10.1055/a-1856-2765
    Database Thieme publisher's database

    More links

    Kategorien

  3. Article ; Online: Update on the use of allergen challenge chambers in immunotherapy: clinical implications.

    Zieglmayer, Petra U / Pfaar, Oliver

    Current opinion in allergy and clinical immunology

    2022  Volume 22, Issue 2, Page(s) 132–136

    Abstract: Purpose of review: This review aims to reflect on and discuss recent evidence of applicability of allergen exposure chambers (AEC) for allergen immunotherapy studies, especially focussing on validation of AECs, technical documentation and future ... ...

    Abstract Purpose of review: This review aims to reflect on and discuss recent evidence of applicability of allergen exposure chambers (AEC) for allergen immunotherapy studies, especially focussing on validation of AECs, technical documentation and future perspectives.
    Recent findings: Publications covered by this review summarize the historical background, current status of research use and validation of AEC systems. It describes identified unmet needs regarding comparability of AEC systems, reproducibility of clinical assessments and correlation of AEC-induced symptoms with scores under natural environmental exposure. Furthermore, new information on technical specifications, for example, dimensions, allergen dispersal and validation procedures is highlighted and future activities of the EAACI AEC task force group regarding harmonization of clinical endpoints are delineated.
    Summary: AECs are in use for evaluation of allergic patients for over three decades now. As different systems largely vary regarding technical set up and standard assessments, detailed technical documentation must be available. To gain acceptance of regulatory authorities for pivotal immunotherapy trials conducted with the use of AEC system, harmonization of clinical assessments as well as documentation of correlation of clinical AEC outcomes with environmental exposure clinical scores is required.
    MeSH term(s) Allergens/therapeutic use ; Desensitization, Immunologic/methods ; Environmental Exposure ; Humans ; Hypersensitivity/diagnosis ; Hypersensitivity/therapy ; Immunologic Factors ; Reproducibility of Results
    Chemical Substances Allergens ; Immunologic Factors
    Language English
    Publishing date 2022-01-20
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2088710-3
    ISSN 1473-6322 ; 1528-4050
    ISSN (online) 1473-6322
    ISSN 1528-4050
    DOI 10.1097/ACI.0000000000000808
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Allergen challenge tests in allergen immunotherapy: State of the art.

    Zieglmayer, Petra / Zieglmayer, René / Lemell, Patrick

    Allergologie select

    2023  Volume 7, Page(s) 25–32

    Abstract: Introduction: Treatment effects in allergen immunotherapy (AIT) studies are based on symptomatic improvement, and evaluations of naturally exposed patients do often show weak efficacy. Allergen challenge tests, such as conjunctival (CAC), nasal (NAC), ... ...

    Abstract Introduction: Treatment effects in allergen immunotherapy (AIT) studies are based on symptomatic improvement, and evaluations of naturally exposed patients do often show weak efficacy. Allergen challenge tests, such as conjunctival (CAC), nasal (NAC), or bronchial (BAC) challenge tests, or challenges in allergen exposure chambers (AEC) are accepted by regulators for AIT phase II studies only.
    Materials and methods: This review aims to describe different allergen challenge test methods, summarizes safety and limitations for each, and discusses their potential for use in AIT trials.
    Results: Organ-specific allergen challenges provide information about individual reactivity, reaction threshold, and organ-specific efficacy of AIT. AECs, targeting all affected organs simultaneously, were developed to investigate disease mechanisms and treatment effects under controlled and reproducible conditions.
    Conclusion: A high level of standardization is existing for NAC only; in CAC and BAC, the toolbox is limited to subjective symptom scoring with no validated objective parameters identified yet. AECs are complex and heterogenous; correlation of systems and comparability of study data is claimed. All challenge methods are safe when conducted by experienced staff.
    Language English
    Publishing date 2023-03-01
    Publishing country Germany
    Document type Journal Article ; Review
    ZDB-ID 2893503-2
    ISSN 2512-8957 ; 2512-8957
    ISSN (online) 2512-8957
    ISSN 2512-8957
    DOI 10.5414/ALX02322E
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Moderne Diagnostik der Typ-1-Allergie

    Zieglmayer, Petra

    Derm

    2018  Volume 24, Issue 2, Page(s) 155

    Language German
    Document type Article
    ZDB-ID 1315453-9
    ISSN 0949-7633
    Database Current Contents Medicine

    More links

    Kategorien

  6. Article: Milben, Tierhaare und Pilze. Neues zu Innenraumallergenen

    Zieglmayer, Petra

    Ars medici

    2017  Volume 107, Issue 9, Page(s) 424

    Language German
    Document type Article
    ZDB-ID 124118-7
    ISSN 0004-2897 ; 2235-5138
    Database Current Contents Medicine

    More links

    Kategorien

  7. Article: Neues zu Innenraumallergenen

    Zieglmayer, Petra

    Der Allgemeinarzt

    2017  Volume 39, Issue 3, Page(s) 58

    Language German
    Document type Article
    ZDB-ID 603653-3
    ISSN 0172-7249
    Database Current Contents Medicine

    More links

    Kategorien

  8. Article: Heuschnupfen unter Kontrolle: Moderne symptomorientierte Therapiekonzepte der allergischen Rhinitis

    Zieglmayer, Petra

    Arzt & Praxis

    2017  Volume 71, Issue 8, Page(s) 21

    Language German
    Document type Article
    ZDB-ID 1224197-0
    ISSN 0048-5128
    Database Current Contents Medicine

    More links

    Kategorien

  9. Article: Carrageenan-Containing Nasal Spray Alleviates Allergic Symptoms in Participants with Grass Pollen Allergy: A Randomized, Controlled, Crossover Clinical Trial.

    Unger-Manhart, Nicole / Morokutti-Kurz, Martina / Zieglmayer, Petra U / Lemell, Patrick / Savli, Markus / Zieglmayer, René / Prieschl-Grassauer, Eva

    International journal of general medicine

    2024  Volume 17, Page(s) 419–428

    Abstract: Purpose: Nonpharmacological, barrier-forming nasal sprays are used to manage symptoms of allergic rhinitis. We aim to evaluate the safety and effectiveness of Callergin (investigational product, IP), a nasal spray containing barrier-forming iota- ... ...

    Abstract Purpose: Nonpharmacological, barrier-forming nasal sprays are used to manage symptoms of allergic rhinitis. We aim to evaluate the safety and effectiveness of Callergin (investigational product, IP), a nasal spray containing barrier-forming iota-carrageenan, in the treatment of allergic rhinitis (AR).
    Methods: In this randomized, controlled, crossover trial, adults with grass pollen allergy underwent a treatment sequence with IP, VisAlpin (comparator product, CP), and no treatment in random order. Treatment blocks consisted in prophylactic administration of the assigned treatment or no treatment, followed by a 3-hr allergen exposure, and were separated by a washout period of 7 days. Primary endpoint was a mean change from baseline in "Total Nasal Symptom Score" (TNSS, sum of rhinorrhea, itching, sneezing, and congestion scores) over 3 hr, recorded every 15 min during the challenge period.
    Results: A total of 42 participants underwent randomization. Exposure to grass pollen for 3 hr induced a notable TNSS increase from baseline in all participants at all times. Mean TNSS change from baseline over 3 hr was lower when participants received IP compared to no treatment, although the difference did not reach statistical significance (untreated 6.96 ± 2.30; IP 6.59 ± 1.93; difference 0.37 points [95% CI (confidence interval) -0.17 to 0.91]; p=0.170). In a post-hoc analysis, mean TNSS at 3 hr was significantly reduced after IP treatment compared to no treatment (untreated 8.29 ± 2.64; IP 7.70 ± 2.56; difference 0.60 points [95% CI -0.10 to 1.29] p=0.028). While all individual nasal symptoms contributed to this effect, rhinorrhea (p=0.013) and congestion (p=0.076) contributed most. Consistently, nasal secretion weight was slightly reduced with IP treatment (p=0.119). IP was safe and well-tolerated, with similar incidence of adverse events across treatment groups.
    Conclusion: Prophylactic treatment with the iota-carrageenan nasal spray IP is safe, well-tolerated, and alleviates nasal allergy symptoms in adults with grass pollen-induced AR.
    Trial registration: NCT04531358.
    Language English
    Publishing date 2024-02-03
    Publishing country New Zealand
    Document type Case Reports ; Clinical Trial
    ZDB-ID 2452220-X
    ISSN 1178-7074
    ISSN 1178-7074
    DOI 10.2147/IJGM.S447359
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Are results of environmental exposure units transferable to real-life exposure?

    Zieglmayer, Petra Ursula

    Current opinion in allergy and clinical immunology

    2013  Volume 13, Issue 3, Page(s) 244–248

    Abstract: Purpose of review: To reflect on and discuss the recent evidence of reliability of the challenge chamber results for real life, especially focusing on the validation of allergen concentrations being 'physiologic' and generating symptoms in the exposed ... ...

    Abstract Purpose of review: To reflect on and discuss the recent evidence of reliability of the challenge chamber results for real life, especially focusing on the validation of allergen concentrations being 'physiologic' and generating symptoms in the exposed volunteers comparable to the natural exposure during pollen season and to the home environment.
    Recent findings: Publications of the last 18 months covered by this review focus on the validation of allergen chamber systems, especially on the quantitative comparison of environmental allergen exposure with allergen challenge chamber (ACC) exposure. It highlights new evidence on the question of relevance of environmental and experimental priming effects and discusses the selection of relevant parameters for the quantification of treatment effects.
    Summary: Benchmarks for validating the ACC systems have been defined and are referred to in clinical ACC trials in increasing amount. So the level of evidence concerning the validity and reliability of allergen chamber systems is steadily growing, especially in allergen-specific models, priming effects and reproducibility of results in the same study population at different time points and with different challenge systems.
    MeSH term(s) Allergens/immunology ; Animals ; Clinical Trials as Topic ; Desensitization, Immunologic ; Drug Dosage Calculations ; Environmental Exposure ; Evidence-Based Medicine ; Humans ; Hypersensitivity/diagnosis ; Hypersensitivity/immunology ; Reproducibility of Results
    Chemical Substances Allergens
    Language English
    Publishing date 2013-06
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2088710-3
    ISSN 1473-6322 ; 1528-4050
    ISSN (online) 1473-6322
    ISSN 1528-4050
    DOI 10.1097/ACI.0b013e328360c7b6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top